Published in Hepatitis Weekly, March 23rd, 2009
“We are pleased with the progress we have made over the last year, resulting in the achievement of three primary goals,” stated Russell H. Plumb, President and CEO of Inhibitex, Inc. “These goals were to successfully complete our Phase I program for FV-100, identify a lead candidate from our series of HCV nucleoside polymerase inhibitors for further preclinical development, and reduce our overhead costs to extend our cash runway in this challenging business environment. Accordingly, we believe we are well positioned to move our development programs to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly